Modulation of VEGF-A alternative splicing as new anti-angiogenic therapeutics

描述（由申请人提供）：癌细胞的主要分子标志是具有拮抗性剪接异构体的基因的异常剪接。这些基因之一是血管内皮生长因子-A（VEGF-A），其可以剪接为典型的促血管生成同种型或抗血管生成同种型。在大多数正常成人组织中，VEGF-A主要剪接为抗血管生成B同种型，而促血管生成同种型在癌细胞中占主导地位以促进新血管的生长。由于持续的血管生成对肿瘤生长和转移至关重要，恢复肿瘤中正常的VEGF-A剪接提出了一种新的抗肿瘤方法。长期目标和具体目标：我们建议通过操纵VEGF-A剪接来开发一种新的抗血管生成方法。这种方法将重新连接协调血管生成的天然剪接调节途径，从而抑制肿瘤生长。本项目有两个具体目标：（1）特异性调节VEGF-A剪接以促进抗血管生成同种型;（2）确定VEGF-A剪接调节作为抗血管生成治疗的体内功效。研究设计和方法使用我们实验室最近开发的一种新技术，我们将产生新的工程剪接因子（ESFs），将VEGF-A的剪接从血管生成异构体转移到抗血管生成异构体。“设计者”ESF将在转移性乳腺癌和肺癌细胞中表达，并且将在mRNA和蛋白质水平上测量抗血管生成VEGF-A剪接同种型的诱导。作为一种补充方法，我们将使用反义寡核苷酸（ASO）将VEGF-A剪接向抗抗原亚型转移。我们将进一步研究VEGF-A下游信号通路对这种剪接调节的反应。此外，我们将使用各种基于细胞的测定来研究剪接调节是否导致血管生成的抑制，并测试剪接调节的脱靶效应。 我们将进一步研究VEGF-A剪接的调节是否可以抑制人类癌症的异种移植小鼠模型中的肿瘤血管生成和生长。我们将用ESFs或ASO预处理的癌细胞注射到SCID小鼠中，以确定剪接调节是否可以抑制异种移植肿瘤的形成和生长。此外，我们将通过瘤内注射或全身递送ESF或ASO直接治疗已建立的异种移植肿瘤，并确定这种治疗是否可以抑制肿瘤进展。我们还将把VEGF-A的联合收割机剪接调节与其他癌症疗法结合起来，看看它们是否具有协同作用，以抑制活体动物的肿瘤进展。

DESCRIPTION (provided by applicant): A major molecular hallmark of cancer cells is the aberrant splicing of genes with antagonistic splice isoforms. One of such genes is the vascular endothelial growth factor-A (VEGF-A) that can be spliced as either canonical pro-angiogenic isoforms or anti-angiogenic isoforms. In most normal adult tissues, VEGF-A is predominantly spliced as the anti-angiogenic b isoforms, whereas the pro-angiogenic isoforms become dominant in cancer cells to promote the growth of new blood vessels. Since sustained angiogenesis is critical to tumor growth and metastasis, restoration of normal VEGF-A splicing of in tumors presents a new anti-tumor approach. Long-term objectives and specific aims: We propose to develop a novel anti-angiogenesis approach by manipulating VEGF-A splicing. Such method will rewire the natural splicing regulatory pathway that orchestrates angiogenesis, thus inhibiting tumor growth. There are two specific aims in this project: (1) Specifically modulate VEGF-A splicing to promote anti- angiogenic isoforms; (2) Determine the in vivo efficacy of VEGF-A splicing modulation as anti-angiogenic therapy. Research design and methods Using a new technique recently developed in our lab, we will generate novel engineered splicing factors (ESFs) to shift the splicing of VEGF-A from angiogenic isoforms to anti-angiogenic isoforms. The "designer" ESFs will be expressed in metastatic breast and lung cancer cells, and the induction of anti-angiogenic VEGF- A splicing isoforms will be measured at mRNA and protein levels. As a complementary approach, we will use antisense oligonucleotides (ASOs) to shift the VEGF-A splicing toward anti-antigenic isoforms. We will further examine the response of the VEGF-A downstream signaling pathway to such splicing modulation. In addition, we will investigate whether the splicing modulation leads to the inhibition of angiogenesis using a variety of cell-based assays, and test the off-target effects of splicing modulation. We will further examine if the modulation of VEGF-A splicing can inhibit the tumor angiogenesis and growth in xenograft mouse model of human cancers. We will inject cancer cells pretreated with ESFs or ASOs into SCID mice to determine if the splicing modulation can inhibit the xenograft tumor formation and growth. Further we will directly treat the established xenograft tumors with intratumoral injection or systematic delivery of ESF or ASOs, and determine if such treatment can inhibit tumor progression. We will also combine splicing modulation of VEGF-A with other cancer therapies to see if they have synergistic effect to inhibit tumor progression in live animals.